Clinical pharmacology in neonates and young infants: The benefit of a population-tailored approach

Expert Review of Clinical Pharmacology

Volumn 5, Issue 1, 2012, Pages 5-8

  Van Den Anker, John ^a,b,c   Allegaert, Karel ^d  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

biomarker; developmental pharmacology; infant; neonate; pharmacodynamics; pharmacokinetics

Indexed keywords

BENZYL ALCOHOL; CHLORAMPHENICOL; DEXAMETHASONE; XENOBIOTIC AGENT;

BRAIN GROWTH; CEREBRAL PALSY; CLINICAL PHARMACOLOGY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG METABOLISM; GASPING SYNDROME; GRAY BABY SYNDROME; HUMAN; PHARMACODYNAMICS; PHENOTYPIC VARIATION; REVIEW; SIDE EFFECT; SYNDROME;

HUMANS; INFANT; INFANT, NEWBORN; PHARMACOLOGY, CLINICAL; POPULATION SURVEILLANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 83055172190     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.65     Document Type: Review

References (15)

1. Van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. Handb. Exp. Pharmacol. 205, 51-75 (2011).
2. Allegaert K, Verbesselt R, Naulaers G et al. Developmental pharmacology: neonates are not just small adults. Acta Clin. Belg. 63(1), 16-24 (2008).
3. Leeder JS, Kearns GL, Spielberg SP, van den Anker J. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J. Clin. Pharmacol. 50(12), 1377-1387 (2010).
4. Jacqz-Aigrain E. Drug policy in Europe research and funding in neonates: current challenges, future perspectives, new opportunities. Early Hum. Dev. 87(Suppl. 1), S27-S30 (2011).
5. George I, Mekahli D, Rayyan M, Levtchenko E, Allegaert K. Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates. Pediatr. Nephrol. 26(10), 1843-1849 (2011).
6. Jacobs S, Hunt R, Tarnow-Mordi W, Inder T, Davis P. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst. Rev. 17(4), CD003311 (2007).
7. van den Berg H, van den Anker JN, Beijnen JH. Cytostatic drugs in infants: a review on pharmacokinetic data in infants. Cancer Treat. Rev. doi:10.1016/j.ctrv.2011.03.005 (2011) (Epub ahead of print).
8. van den Anker JN, Allegaert K. Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress? Eur. J. Clin. Pharmacol. 65(11), 1159-1160 (2009).
9. De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. The role of population PK-PD modelling in paediatric clinical research. Eur. J. Clin. Pharmacol. 67(Suppl. 1), 5-16 (2011).
10. Kearns GL. Beyond biomarkers: an opportunity to address the 'pharmacodynamic gap' in pediatric drug development. Biomark. Med. 4(6), 783-786 (2010).
11. Mussap M, Fanos V. Neonatal nephrology and laboratory medicine: an effective interdisciplinary model to improve the outcome in neonatal intensive care unit. J. Matern. Fetal Neonatal Med. 24(Suppl. 2), S2-S3 (2011).
12. Kern SE. Challenges in conducting clinical trials in children: approaches for improving performance. Exp. Rev. Clin. Pharmacol. 2(6), 609-617 (2009).
13. Mulder H, Pitchford NH, Marlow N. Inattentive behaviour is associated with poor working memory and slow processing speed in very pre-term children in middle childhood. Br. J. Educ. Psychol. 81(Pt 1), 147-160 (2011).
14. Farombi-Oghuvbu I, Matthews T, Mayne PD, Guerin H, Corcoran JD. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch. Dis. Child. Fetal Neonatal Ed. 93(4), F257-F260 (2008).
15. Kuppens M, George I, Lewi L, Levtchenko E, Allegaert K. Creatinaemia at birth is equal to maternal creatinaemia at delivery: does this paradigm still hold? J. Matern. Fetal Neonatal Med. doi:10.3109/1 4767058.2011.602144 (2011) (Epub ahead of print).